Observational studyVascular health and risk management2026
Effectiveness of Conservative Treatment on Chronic Venous Disease Symptoms and Quality of Life in Patients with Type 2 Diabetes: Results from a Subanalysis of the VEIN STEP Observational Study.
Observational study in Vascular health and risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04574375 (A Prospective, Observational), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Observational (Non-interventional), International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This post-hoc subanalysis of the VEIN STEP study assessed the effectiveness of conservative treatment, particularly venoactive drugs (VAD), in reducing chronic venous disease (CVD) signs and symptoms and improving quality of life (QoL) for patients with type 2 diabetes (T2D) in a real-life setting. Methods: VEIN STEP was an observational, prospective study conducted in adult outpatients who consulted for symptomatic CVD (NCT04574375). CVD symptoms (10-cm Visual Analog Scale and Patient Global Impression of Change), disease severity (Venous Clinical Severity Score), and QoL (Chronic Venous Insufficiency Questionnaire [CIVIQ-14]) were assessed. Results: Overall, 6084 patients were analyzed, of whom 702 (11.5%) had T2D. These patients were more likely to be older, present with a more advanced CEAP class, have a higher body mass index, greater symptom severity and reduced QoL scores than those without T2D (p<0.001 for all). Almost all patients with T2D (97.3%) received VAD-based treatment, mainly micronized purified flavonoid fraction (MPFF, 72.2%) or diosmin (24.6%). After 4 weeks, conservative therapy was associated with significant improvements in CVD symptoms and QoL (p<0.001). Physicians also noted a significant improvement in disease severity (p<0.001). The decrease in global symptom intensity was significantly greater among patients treated with MPFF than in those treated with diosmin (mean -2.7±1.8 vs -2.0±1.8, p=0.004). Greater reductions in symptom intensity were also observed in patients treated with MPFF for pain (p=0.011), leg heaviness (p=0.006), and swelling (p=0.014), with a tendency for greater improvement of cramps. QoL improved for patients receiving MPFF and those receiving diosmin, with changes in CIVIQ-14 global index score of -21.3±15.8 and -15.5±14.6, respectively. Conclusion: These findings indicate that patients with concomitant CVD and T2D are more likely to have greater symptom severity and disease burden. In such patients, VAD-based conservative therapy, particularly MPFF, was associated with significant improvements in CVD-related symptoms and QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.